Products

Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Biotinylated Human VEGF165, epitope tag free, ultra sensitivity (primary amine labeling), 200 µg  

Recombinant Biotinylated Human VEGF165, epitope tag free, ultra sensitivity (primary amine labeling), 200 µg

Recombinant Biotinylated Human VEGF165, Ala 27 - Arg 191, ultra sensitivity (primary amine labeling), expressed from human HEK293 cells, epitope tag free

Synonym: recombinant, human, biotinylated protein, RP1-261G23.1, MGC70609, MVCD1, VEGFA, VPF, VEGF165, biotin-VEGF, btn-VEGF

More details

VE5-H8210-200

1 580,00 €

Background:
VEGF165
is the most abundant splice variant of VEGF-A. VEGF165 is produced by a number of cells including endothelial cells, macrophages and T cells. VEGF165 is involved in angiogenesis, vascular endothelial cell survival, growth, migration and vascular permeability. VEGF gene expression is induced by hypoxia, inflammatory cytokines and oncogenes. VEGF165 binds to heparan sulfate and is retained on the cell surface and in the extracellular matrix. VEGF165 binds to the receptor tyrosine kinases, VEGFR1 and VEGFR2. VEGF165 is the only splice variant that binds to co-receptors NRP-1 and NRP-2 that function to enhance VEGFR2 signaling. Binding of VEGF165 to VEGFR1 and VEGFR2 leads to activation of the PI3K/AKT, p38 MAPK, FAK and paxillin. VEGF plays a key role in tumor angiogenesis in many cancers.

The primary amine of rhVEGF165 was labeled by biotin without decreasing its bioactivity, and has been used successfully for easy detection in ELISA, dot blot or Western blot, immunohistochemistry applications using streptavidin or avidin-conjugated probes. Biotin and other reactive related chemicals have been removed thoroughly by desalting after reaction termination.

Source
Recombinant MABSol® Biotinylated Biotinylated Human VEGF165, epitope tag free, primary amine labeling (VE5-H8210) is expressed from human HEK293 cells. It contains AA Ala 27 - Arg 191 (Accession # NP_001165097). It is the biotinylated form of ActiveMax® Human VEGF165, Tag Free (HPLC-verified) (VE5-H4210).
Predicted N-terminus: Ala 27

Molecular Characterization
This protein carries no "tag".
The protein has a calculated MW of 19.2 kDa. As a result of glycosylation, the protein migrates as 25-30 kDa (monomer) under reducing (R) condition, and 43-50 kDa under non-reducing (NR) condition (SDS-PAGE).

Biotinylation
The primary amines in the side chains of lysine residues and the N-terminus of the protein are conjugated with biotins using standard chemical labeling method. A standard biotin reagent (13.5 angstroms) is used in this product.

Biotin:Protein Ratio
Passed as determined by the HABA assay / binding ELISA.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE. 

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Reconstitution
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the COA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 24 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Spatiotemporally controlled, aptamers-mediated growth factor release locally manipulates microvasculature formation within engineered tissues"
Rana, Kandar, Salehi-Nik et al
Bioact Mater (2022) 12, 71-84
(2) "Synthesis, Physicochemical and Biological Study of Gallium-68- and Lutetium-177-Labeled VEGF-A165/NRP-1 Complex Inhibitors Based on Peptide A7R and Branched Peptidomimetic"
Masłowska, Witkowska, Tymecka et al
Pharmaceutics (2022) 14 (1)
(3) "Peptide-Modified Nano-Bioactive Glass for Targeted Immobilization of Native VEGF"
Schumacher, Habibović, van Rijt
ACS Appl Mater Interfaces (2022) 14 (4), 4959-4968
Showing 1-3 of 1210 papers.

Citations

(1) "CHLOROTOXIN AGENTS AND USES THEREOF "
Authors: Mcgonigle Sharon,Majumder Utpal,Postema Maarten H D.
Journal: US20200206312A1 2020
Application: Binding Assay
(2) "Neuropilin-1 drives tumor-specific uptake of chlorotoxin "
Authors: McGonigle S, et al
Journal: Cell Commun Signal 2019
Application: BLI
(3) "N-terminal syndecan-2 domain selectively enhances 6-O heparan sulfate chains sulfation and promotes VEGFA 165-dependent neovascularization"
Authors: F Corti, et al
Journal: Nat Commun 2019
Application: ELISA

 



 

 

The following products could also be interesting for you: